Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2006.02791.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
State-of-the-art diagnosis of autoimmune blistering diseases.
Front Immunol
June 2024
Department of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany.
Article Synopsis
- - Autoimmune blistering disorders (AIBDs) include various conditions such as pemphigus and pemphigoid, characterized by blisters and skin lesions that can have diverse appearances, making accurate diagnosis essential for treatment and prognosis.
- - Diagnosis typically combines clinical evaluation with the detection of specific autoantibodies, utilizing tests like enzyme-linked immunosorbent assay (ELISA) and direct immunofluorescence microscopy (IFM), which is considered the gold standard.
- - Recent advancements in molecular identification of target antigens have led to new diagnostic methods and treatment approaches, enhancing the ability to detect specific antibodies related to various AIBDs.
Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis-A Single-Center Experience.
J Pers Med
April 2024
Department of Rheumatology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
(1) Background: Although the association between psoriasis and atopic dermatitis (AD) is reported in the literature, scarce data are known about the efficacy of biologic therapy (including TNF and IL-17 inhibitors) in patients with psoriatic arthritis (PsA) and concomitant AD. (2) Objective: We aimed to explore AD in patients with PsA undergoing biologics for their active disease, focusing on prevalence and clinical and potential therapeutic implications. (3) Material and methods: We performed a retrospective analysis of 64 patients with PsA receiving various biological agents, followed-up in an academic outpatient rheumatology department up to 10 years.
View Article and Find Full Text PDFEfficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years.
Br J Dermatol
July 2024
Clinical Development Department, Maruho Co. Ltd, Kyoto, Japan.
Article Synopsis
- Prurigo nodularis (PN) is a long-term skin condition that impacts the quality of life, and treatment options in Japan are limited.
- A study tested the safety and effectiveness of the drug nemolizumab at two different doses (30 mg and 60 mg) compared to a placebo over 16 weeks in patients with PN.
- Results showed significant reductions in itching and improvements in skin condition, sleep, and quality of life for those taking nemolizumab, with both doses being well tolerated.*
Long-term therapeutic response to dupilumab in patients affected by prurigo nodularis: A real-world retrospective study.
J Eur Acad Dermatol Venereol
October 2024
Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
Clinical Characteristics and Treatment Outcomes of Prurigo Nodularis: A Retrospective Study.
J Cutan Med Surg
April 2024
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada.
Article Synopsis
- Prurigo nodularis (PN) is a chronic skin condition marked by intense itching and nodules, often linked to mental health issues and other medical conditions.
- A study involving 81 adult patients revealed that nearly 79% had mental health disorders, with itching and dry skin being the most frequent symptoms.
- Treatments like cyclosporine, methotrexate, and narrow band ultraviolet (NB-UVB) showed notable effectiveness in alleviating itching, but clinicians should be aware of possible side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!